LANDMARK 试验:新一代 Myval 经导管心脏瓣膜系列与当代瓣膜(Sapien 和 Evolut)在真实世界重度症状性自体主动脉瓣狭窄患者中早期结局的随机非劣效性比较
LANDMARK 是一项前瞻性、跨国、随机、开放标签、非劣效性试验,在 16 个国家 31 家医院纳入 768 例重度症状性自体主动脉瓣狭窄患者,1:1 随机分配至 Myval 经导管心脏瓣膜系列或当代瓣膜(Sapien 系列或 Evolut 系列)。主要终点为 30 天复合终点(全因死亡、全部卒中、出血 3-4 型、急性肾损伤 2-4 期、主要血管并发症、中度或重度人工瓣膜反流、导致永久起搏器植入的传导系统障碍),非劣效界值 10.44%,假设事件率 26.10%。结果 Myval 组主要终点 25% vs 当代瓣膜组 27%,风险差 -2.3%(单侧 95%CI 上限 3.8,非劣效性 P<0.0001),主要复合终点各单项组分无显著差异。作者结论为 Myval THV 在 30 天达到主要终点。
要点
- Myval 组 30 天主要复合终点 25% vs 当代瓣膜组 27%,风险差 -2.3%(单侧 95%CI 上限 3.8,非劣效性 P<0.0001),达到非劣效界值 10.44%。
- 主要复合终点各单项组分(全因死亡、全部卒中、出血 3-4 型、急性肾损伤 2-4 期、主要血管并发症、中度或重度人工瓣膜反流、导致永久起搏器植入的传导系统障碍)两组间无显著差异。
- Myval 瓣膜直径以 1.5 mm 递增,便于与主动脉瓣环精确匹配;当代瓣膜尺寸通常以 3 mm 递增。
- 研究纳入 768 例重度症状性自体主动脉瓣狭窄患者,平均年龄 Myval 组 80.0 岁(SD 5.7)vs 当代瓣膜组 80.4 岁(SD 5.4),STS 评分中位数两组均为 2.6%(IQR 1.7-4.0)。
- 适用性由心脏团队根据 2021 年欧洲心脏病学会指南决定,主要终点按第三版瓣膜学术研究联盟标准定义。
适用人群与场景
- 重度症状性自体主动脉瓣狭窄患者,适用性主要由心脏团队根据 2021 年欧洲心脏病学会指南决定。
- 纳入 768 例,随机分至 Myval THV 组 384 例或当代 THV 组 384 例;369 例(48%)记录为女性,399 例(52%)为男性。
- 平均年龄:Myval 组 80.0 岁(SD 5.7),当代瓣膜组 80.4 岁(SD 5.4);STS 评分中位数两组均为 2.6%(IQR 1.7-4.0)。
诊断标准与关键阈值
- 主要终点按第三版瓣膜学术研究联盟标准定义,为 30 天复合终点:全因死亡、全部卒中、出血(3 型和 4 型)、急性肾损伤(2-4 期)、主要血管并发症、中度或重度人工瓣膜反流、导致永久起搏器植入的传导系统障碍。
- 非劣效性检验在意向治疗人群中进行,非劣效界值 10.44%,假设事件率 26.10%。
研究设计与关键结果
- 研究类型:前瞻性、跨国、随机、开放标签、非劣效性试验,在 16 个国家(德国、法国、瑞典、荷兰、意大利、西班牙、新西兰、葡萄牙、希腊、匈牙利、波兰、斯洛伐克、斯洛文尼亚、克罗地亚、爱沙尼亚和巴西)31 家医院开展,纳入 768 例重度症状性自体主动脉瓣狭窄患者,1:1 随机分配至 Myval THV 或当代 THV(Sapien 系列或 Evolut 系列)。
- 主要终点:Myval 组 25% vs 当代瓣膜组 27%,风险差 -2.3%(单侧 95%CI 上限 3.8,非劣效性 P<0.0001),达到非劣效性。
- 主要复合终点各单项组分两组间无显著差异。
- 研究时间:2021 年 1 月 6 日至 2023 年 12 月 5 日随机分配;试验注册号 ClinicalTrials.gov NCT04275726,EudraCT 2020-000137-40,已停止纳入新参与者。
证据类型、等级与局限
- 证据类型:前瞻性、跨国、随机、开放标签、非劣效性试验。
- 作者结论:在重度症状性自体主动脉瓣狭窄患者中,Myval THV 在 30 天达到主要终点。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在重度症状性自体主动脉瓣狭窄患者中,Myval THV 在 30 天达到主要终点(非劣于当代瓣膜)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Transcatheter aortic valve implantation is an established, guideline-endorsed treatment for severe aortic stenosis. Precise sizing of the balloon-expandable Myval transcatheter heart valve (THV) series with the aortic annulus is facilitated by increasing its diameter in 1·5 mm increments, compared with the usual 3 mm increments in valve size. The LANDMARK trial aimed to show non-inferiority of the Myval THV series compared with the contemporary THVs Sapien Series (Edwards Lifesciences, Irvine, CA, USA) or Evolut Series (Medtronic, Minneapolis, MN, USA).
METHODS: In this prospective, multinational, randomised, open-label, non-inferiority trial across 31 hospitals in 16 countries (Germany, France, Sweden, the Netherlands, Italy, Spain, New Zealand, Portugal, Greece, Hungary, Poland, Slovakia, Slovenia, Croatia, Estonia, and Brazil), 768 participants with severe symptomatic native aortic stenosis were randomly assigned (1:1) to the Myval THV or a contemporary THV. Eligibility was primarily decided by the heart team in accordance with 2021 European Society of Cardiology guidelines. As per the criteria of the third Valve Academic Research Consortium, the primary endpoint at 30 days was a composite of all-cause mortality, all stroke, bleeding (types 3 and 4), acute kidney injury (stages 2-4), major vascular complications, moderate or severe prosthetic valve regurgitation, and conduction system disturbances resulting in a permanent pacemaker implantation. Non-inferiority of the study device was tested in the intention-to-treat population using a non-inferiority margin of 10·44% and assuming an event rate of 26·10%. This trial is registered with ClinicalTrials.gov, NCT04275726, and EudraCT, 2020-000137-40, and is closed to new participants.
FINDINGS: Between Jan 6, 2021, and Dec 5, 2023, 768 participants with severe symptomatic native aortic stenosis were randomly assigned, 384 to the Myval THV and 384 to a contemporary THV. 369 (48%) participants had their sex recorded as female, and 399 (52%) as male. The mean age of participants was 80·0 years (SD 5·7) for those treated with the Myval THV and 80·4 years (5·4) for those treated with a contemporary THV. Median Society of Thoracic Surgeons scores were the same in both groups (Myval 2·6% [IQR 1·7-4·0] vs contemporary 2·6% [1·7-4·0]). The primary endpoint showed non-inferiority of the Myval (25%) compared with contemporary THV (27%), with a risk difference of -2·3% (one-sided upper 95% CI 3·8, pnon-inferiority<0·0001). No significant difference was seen in individual components of the primary composite endpoint.
INTERPRETATION: In individuals with severe symptomatic native aortic stenosis, the Myval THV met its primary endpoint at 30 days.
FUNDING: Meril Life Sciences.
参考来源
- Baumbach A, van Royen N, Amat-Santos IJ, et al. LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial. Lancet. 2024. PMID: 38795719. doi:10.1016/S0140-6736(24)00821-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。